Personalised treatment of patients with immune thrombotic thrombocytopenic purpura

Background. Treatment of immune thrombotic thrombocytopenic purpura (iTTP) includes plasma exchange (PEX) and immunosuppression (glucocorticoids and rituximab). The addition of caplacizumab to therapy has improved treatment outcomes in iTTP. However, the available therapies focus on the duration of...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Gennady M. Galstyan, Elizaveta E. Klebanova, Svetlana Yu. Mamleeva, Pavel V. Avdonin, Zalina T. Fidarova, Mikhail Yu. Drokov, Elena N. Parovichnikova
Formatua:	Artigo
Hizkuntza:	Russo
Argitaratua:	"Consilium Medicum" Publishing house 2025-01-01
Saila:	Терапевтический архив
Gaiak:	thrombotic thrombocytopenic purpura adamts13 plasma exchange glucocorticoids caplacizumab rituximab bortezomib
Sarrera elektronikoa:	https://ter-arkhiv.ru/0040-3660/article/viewFile/680623/205519
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!